Institute for Regenerative Medicine (IREM), University of Zurich, Zurich, Switzerland.
Wyss Zurich, University and ETH Zurich, Zurich, Switzerland.
Stem Cells Transl Med. 2023 Mar 3;12(2):72-82. doi: 10.1093/stcltm/szad002.
Cardiovascular disease is a major cause of morbidity and mortality worldwide and, to date, the clinically available prostheses still present several limitations. The design of next-generation regenerative replacements either based on cellular or extracellular matrix technologies can address these shortcomings. Therefore, tissue engineered constructs could potentially become a promising alterative to the current therapeutic options for patients with cardiovascular diseases. In this review, we selectively present an overview of the current tissue engineering tools such as induced pluripotent stem cells, biomimetic materials, computational modeling, and additive manufacturing technologies, with a focus on their application to translational cardiovascular therapies. We discuss how these advanced technologies can help the development of biomimetic tissue engineered constructs and we finally summarize the latest clinical evidence for their use, and their potential therapeutic outcome.
心血管疾病是全球发病率和死亡率的主要原因，迄今为止，临床上可用的假体仍然存在一些局限性。基于细胞或细胞外基质技术的下一代再生替代品的设计可以解决这些缺点。因此，组织工程构建物可能成为治疗心血管疾病患者的当前治疗选择的有前途的替代方法。在这篇综述中，我们选择性地概述了当前的组织工程工具，如诱导多能干细胞、仿生材料、计算建模和增材制造技术，并重点介绍了它们在转化心血管治疗中的应用。我们讨论了这些先进技术如何帮助仿生组织工程构建物的发展，最后总结了它们的最新临床应用证据及其潜在的治疗效果。
